Machine Learning

A Japanese chemical plant's new AI-powered microgrid reveals how firms are using renewables not just for ESG, but as a defense against disaster and grid failure.

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?

With its AI & Autonomy Day, Rivian is betting its future on software. Investors are watching to see if its tech can deliver a true competitive edge.

Imviva Biotech's 'ready-to-use' CAR-T therapy shows breakthrough results, offering new hope and eliminating life-threatening waits for leukemia patients.

Following a major clinical trial win, Kymera Therapeutics seeks $500M. We break down the high-stakes strategy behind funding a new era of medicine.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

When a 'living drug' for cancer fails, hope fades. A new biologic aims to repaint the target, giving patients' own immune cells a second chance to win.

NJBIZ honors Tevogen for its innovation, but can the biotech firm turn its ambitious multi-billion-dollar forecasts into reality? A deep dive.

A tech-enabled CRO enrolled 550+ oncology patients in six months, a feat that signals a major disruption to the slow, costly drug development process.

A Japanese EdTech firm is offering unlimited free English lessons in Brazil. Is this a savvy market capture or a high-risk gamble in a crowded space?

As consumer debt soars, a key advocacy group's new data-focused leadership could turn a powerful analytical lens on the role of healthcare and drug prices.

Paychex is betting on AI to transform HR, from automating payroll to mining unstructured data. Is this the future of workforce management?

A new point-of-care PCR test is moving closer to reality in India, promising to revolutionize the fight against tuberculosis and cervical cancer.

Nokia is doubling down on open networking with SONiC, a strategic move to challenge proprietary giants and carve out a crucial role in AI infrastructure.

A Houston biotech reports a 100% response rate with its new CAR-T therapy, offering a potential lifeline for patients with a devastatingly rare cancer.

Nova Era Labs promises to revolutionize AI education with virtual labs. But in a market of giants, can it deliver on its bold claims of workforce readiness?

A new flooring finish promises unprecedented durability and safety, transforming high-traffic commercial spaces from clinics to retail boutiques.

The ADA’s new standards push for tech from day one and holistic care, but can the system deliver this innovative future to every patient?

As the humanoid robotics market soars towards $7.7B, one firm is recruiting top talent to find the next big winner. What does this move signal to investors?

A new partnership aims to advance a novel antibody for FTLD, a devastating dementia, showcasing a powerful model for biotech innovation and strategic growth.